Holen Sie sich die Stockscreener-App
2.03
4.10%
0.08
Vorhandelsmarkt:
2.00
-0.03
-1.48%
Palisade Bio Inc Aktie (PALI) Neueste Nachrichten
Palisade Bio Inc (PALI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Palisade Bio Inc (PALI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palisade Bio Inc (PALI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PALI|Palisade Bio Inc|Price:1.950|Chg%:-0.070 - TradingKey
TradingKey - TradingKey
Palisade Bio Inc (PALI) Institutional Confidence - TradingKey
Palisade Bio Inc. (PALI) Dips 3.5% as Shares Test Key Support at $1.85Reversal Setup Alerts - dars.gov.et
Palisade Bio Inc (PALI) Cash Flow - TradingKey
Palisade Bio Inc (PALI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis - Benzinga
PALI Initiates Coverage On by Oppenheimer -- Rating 'Outperform' - GuruFocus
Palisade Bio jumps following Oppenheimer outperform initiation (PALI:NASDAQ) - Seeking Alpha
Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target - marketscreener.com
Enterprise value to revenue forward of Palisade Bio, Inc. – LS:A4098S - TradingView
Insider Buying: Robert Baltera Acquires 45,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock By Investing.com - Investing.com India
Form 4 Palisade Bio Inc For: 10 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock - Investing.com UK
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - The Manila Times
Palisade Bio to present clinical updates at Lee... - Pluang
Palisade Bio leaders set to outline IBD drug plans at Boston forum - Stock Titan
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets - Seeking Alpha
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock By Investing.com - Investing.com UK
Insider Buying: Robert Baltera Acquires 50,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com - Investing.com Nigeria
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
Palisade Bio CEO, CFO Finley sells $303k in stock By Investing.com - Investing.com South Africa
Palisade Bio chief medical officer Jones sells $106,535 in stock - Investing.com
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock - Investing.com
Palisade Bio CEO, CFO Finley sells $303k in stock - Investing.com
Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys - Stock Titan
[Form 4] PALISADE BIO, INC. Insider Trading Activity - Stock Titan
Palisade Bio (PALI) CEO Finley sells shares to cover RSU tax - Stock Titan
Stifel Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Insider Spends US$59k Buying More Shares In Palisade Bio - simplywall.st
Palisade Bio Inc. (PALI) Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D FocusPre-Earnings Drift - dars.gov.et
Form 144 PALISADE BIO For: 7 July By Investing.com - Investing.com Nigeria
[144] PALISADE BIO, INC. SEC Filing - Stock Titan
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock - Investing.com
Form 4 Palisade Bio Inc For: 6 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. buys $59,400 in stock By Investing.com - Investing.com South Africa
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):